Pucotenlimab
As of the edition of 20 October 2026, Pucotenlimab is an antibody: in active development; acts on PDCD1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 62, 0 stopped early
- Disease areas
- Cancer; Digestive system; Skin and connective tissue; Urinary and reproductive; Ear, nose and throat; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PDCD1 | Programmed cell death protein 1 | Q15116 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 1 | 6 | 0 | 2 | 0 |
| Phase 2 | 48 | 2 | 37 | 0 |
| Phase 3 | 7 | 0 | 4 | 0 |
| All trials | 62 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Taizhou Hanzhong biomedical | Lead sponsor of trials | 2018 to now |
| Taizhou HoudeAoke Biomedical | Lead sponsor of trials | 2020 to now |
| Binhui Biopharmaceutical | Lead sponsor of trials | 2020 to now |
| Lepu Biopharma | Lead sponsor of trials | 2021 to now |
| Shanghai Miracogen | Lead sponsor of trials | 2022 to now |